According to a recent LinkedIn post from Elanco, company President and CEO Jeff Simmons appears in a new Shared Table episode with the CEOs of IDEXX and Mission Pet Health to discuss diagnostics and artificial intelligence in pet care. The discussion is framed around the idea that effective treatment depends on proper diagnosis, with the post noting that only one in five pets currently receive diagnostics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests there is substantial untapped potential in expanding diagnostic usage, particularly as pets acquired during the pandemic move into higher-care years. For investors, this emphasis on diagnostics and AI may signal strategic focus on higher-value, data-driven services and products that could support revenue growth and deepen partnerships across the companion-animal health ecosystem.
By highlighting innovation that aims to extend both the length and quality of pets’ lives, the content points to a long-term demand driver for veterinary pharmaceuticals, diagnostics, and related technologies. If Elanco can position itself as a key player in this evolving diagnostic-centric model of care, it could enhance its competitive standing relative to peers and potentially benefit from increased recurring spend per pet over time.